| NetPath: a public resource of curated signal transduction pathways K Kandasamy, SS Mohan, R Raju, S Keerthikumar, GSS Kumar, ... Genome biology 11, 1-9, 2010 | 534 | 2010 |
| Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants I Chachoua, C Pecquet, M El-Khoury, H Nivarthi, RI Albu, C Marty, ... Blood, The Journal of the American Society of Hematology 127 (10), 1325-1335, 2016 | 363 | 2016 |
| Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis C Marty, C Pecquet, H Nivarthi, M El-Khoury, I Chachoua, M Tulliez, ... Blood, The Journal of the American Society of Hematology 127 (10), 1317-1324, 2016 | 290 | 2016 |
| Mining for JAK–STAT mutations in cancer SN Constantinescu, M Girardot, C Pecquet Trends in biochemical sciences 33 (3), 122-131, 2008 | 219 | 2008 |
| Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias N Harir, C Pecquet, M Kerenyi, K Sonneck, B Kovacic, R Nyga, M Brevet, ... Blood 109 (4), 1678-1686, 2007 | 154 | 2007 |
| miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets M Girardot, C Pecquet, S Boukour, L Knoops, A Ferrant, W Vainchenker, ... Blood, The Journal of the American Society of Hematology 116 (3), 437-445, 2010 | 150 | 2010 |
| Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/MAPK pathways via the Gab2 scaffolding adapter R Nyga, C Pecquet, N Harir, H Gu, I Dhennin-Duthille, A Régnier, ... Biochemical Journal 390 (1), 359-366, 2005 | 130 | 2005 |
| JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors A Dusa, C Mouton, C Pecquet, M Herman, SN Constantinescu PloS one 5 (6), e11157, 2010 | 107 | 2010 |
| Orientation‐specific signalling by thrombopoietin receptor dimers J Staerk, JP Defour, C Pecquet, E Leroy, H Antoine‐Poirel, I Brett, M Itaya, ... The EMBO journal 30 (21), 4398-4413, 2011 | 96 | 2011 |
| Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor C Pecquet, J Staerk, R Chaligné, V Goss, KA Lee, X Zhang, J Rush, ... Blood, The Journal of the American Society of Hematology 115 (5), 1037-1048, 2010 | 96 | 2010 |
| Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors C Marty, C Saint-Martin, C Pecquet, S Grosjean, J Saliba, C Mouton, ... Blood, The Journal of the American Society of Hematology 123 (9), 1372-1383, 2014 | 92 | 2014 |
| Tryptophan at the transmembrane–cytosolic junction modulates thrombopoietin receptor dimerization and activation JP Defour, M Itaya, V Gryshkova, IC Brett, C Pecquet, T Sato, SO Smith, ... Proceedings of the National Academy of Sciences 110 (7), 2540-2545, 2013 | 92 | 2013 |
| Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants C Pecquet, I Chachoua, A Roy, T Balligand, G Vertenoeil, E Leroy, ... Blood, The Journal of the American Society of Hematology 133 (25), 2669-2681, 2019 | 91 | 2019 |
| The thrombopoietin receptor: structural basis of traffic and activation by ligand, mutations, agonists, and mutated calreticulin LN Varghese, JP Defour, C Pecquet, SN Constantinescu Frontiers in endocrinology 8, 59, 2017 | 89 | 2017 |
| PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib FA Arts, D Chand, C Pecquet, AI Velghe, S Constantinescu, B Hallberg, ... Oncogene 35 (25), 3239-3248, 2016 | 87 | 2016 |
| Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms JP Defour, I Chachoua, C Pecquet, SN Constantinescu Leukemia 30 (5), 1214-1216, 2016 | 81 | 2016 |
| Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2 A Dusa, J Staerk, J Elliott, C Pecquet, HA Poirel, JA Johnston, ... Journal of Biological Chemistry 283 (19), 12941-12948, 2008 | 78 | 2008 |
| Thrombopoietin receptor is required for the oncogenic function of CALR mutants H Nivarthi, D Chen, C Cleary, B Kubesova, R Jäger, E Bogner, C Marty, ... Leukemia 30 (8), 1759-1763, 2016 | 72 | 2016 |
| Combination treatment for myeloproliferative neoplasms using JAK and pan‐class I PI 3K inhibitors ML Choong, C Pecquet, V Pendharkar, CC Diaconu, JWY Yong, SJ Tai, ... Journal of cellular and molecular medicine 17 (11), 1397-1409, 2013 | 69 | 2013 |
| MicroRNAs in platelet biogenesis and function S Dangwal, T Thum Thrombosis and haemostasis 108 (10), 599-604, 2012 | 67 | 2012 |
